Pure Green Pharmaceuticals Report issue

For profit Phase 2

Organization Overview

First Clinical Trial
2020
NCT04679545
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pure Green Pharmaceuticals | Pure Green Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

cannabidiol (Epidiolex) (2 trials)

tetrahydrocannabinol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuralgia (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2